Armata Pharmaceuticals
ARMP
24 hedge funds and large institutions have $2.57M invested in Armata Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 2 closing their positions.
0.01% more ownership
Funds ownership: 3.83% → 3.84% (+0.01%)
0% more funds holding
Funds holding: 24 → 24 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
22% less capital invested
Capital invested by funds: $3.28M → $2.57M (-$710K)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $22K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$45K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$8.89K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.94K |
| 5 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$160 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
-$19.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$18.5K |
| 3 |
Renaissance Technologies
New York
|
-$13.9K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$12.8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$623 |
ARMP Hedge Fund Activity: Q4 2024 in Review
24 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q4 2024, worth a combined $2.57M — down 22% from $3.28M a quarter earlier.
Fund positioning in ARMP was balanced in Q4 2024: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 7 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $45K. The largest seller was Group One Trading, cutting an estimated $19.6K.
- 24 institutional investors held Armata Pharmaceuticals (ARMP) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $2.57M of Armata Pharmaceuticals stock for Q4 2024, down 22% quarter-over-quarter.
- 2 funds opened new Armata Pharmaceuticals positions in Q4 2024 and 2 closed out, a net change of 0 holders.
- The largest Armata Pharmaceuticals buyer in Q4 2024 was Susquehanna International Group, an estimated $45K added.
- The largest Armata Pharmaceuticals seller in Q4 2024 was Group One Trading, an estimated $19.6K sold.
Based on aggregated 13F filings for Q4 2024.